{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "9784173", "DateCompleted": {"Year": "1998", "Month": "11", "Day": "30"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "11"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0163-3864", "JournalIssue": {"Volume": "61", "Issue": "10", "PubDate": {"Year": "1998", "Month": "Oct"}}, "Title": "Journal of natural products", "ISOAbbreviation": "J Nat Prod"}, "ArticleTitle": "New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus.", "Pagination": {"StartPage": "1295", "EndPage": "1297", "MedlinePgn": "1295-7"}, "Abstract": {"AbstractText": ["Two new iridoid glycosides (1 and 2), together with the known compounds barlerin (3) and verbascoside (4), were isolated from Barleria prionitis. The new iridoid glycosides were determined to be 6-O-trans-p-coumaroyl-8-O-acetylshanzhiside methyl ester (1) and its cis isomer (2) by using spectroscopic, especially 2D NMR, data. A 3:1 mixture of 1 and 2 was shown to have potent in vitro activity against respiratory syncytial virus (EC50 2.46 microgram/mL, IC50 42.2 microgram/mL)."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shaman Pharmaceuticals, Inc., 213 East Grand Avenue, South San Francisco, California 94080, USA."}], "LastName": "Chen", "ForeName": "J L", "Initials": "JL"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Blanc", "ForeName": "P", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Stoddart", "ForeName": "C A", "Initials": "CA"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Bogan", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Rozhon", "ForeName": "E J", "Initials": "EJ"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Parkinson", "ForeName": "N", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Ye", "ForeName": "Z", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Cooper", "ForeName": "R", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Balick", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Nanakorn", "ForeName": "W", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Kernan", "ForeName": "M R", "Initials": "MR"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Nat Prod", "NlmUniqueID": "7906882", "ISSNLinking": "0163-3864"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "6-O-4-coumaroyl-8-O-acetylshanzhiside methyl ester"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Glycosides"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "isolation & purification", "pharmacology"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Cytopathogenic Effect, Viral"}, {"QualifierName": ["chemistry", "isolation & purification", "pharmacology"], "DescriptorName": "Glycosides"}, {"QualifierName": [], "DescriptorName": "Magnetic Resonance Spectroscopy"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Respiratory Syncytial Viruses"}, {"QualifierName": [], "DescriptorName": "Thailand"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1998", "Month": "10", "Day": "24"}, {"Year": "1998", "Month": "10", "Day": "24", "Hour": "0", "Minute": "1"}, {"Year": "1998", "Month": "10", "Day": "24", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["9784173", "10.1021/np980086y", "np980086y"]}}]}